focus -WSS

focus

author：entertainment 2025-10-01 12:54:59 - browse：3

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Is it ever OK for doctors to lie to their patients?

WSS

What is artificial intelligence? Experts weigh in

Crowdfunding for medical bills sidesteps core problem, author says

Has Bernie Sanders reached the limit of his pharma bullying effort?

Novel spinal cord stimulator treats paralysis without surgery

As billionaires fund anti

Biden White House, tech companies launch new safeguards around emerging AI technology

hotspot

focus

hotspot

Supreme Court strikes down use of affirmative action

How Brent Saunders' Allergan experiment failed

Medicare proposal to cover medical devices draws a mixed reaction

New chief aims to remake Sanofi Genzyme

Psychedelics group wrestles with new pharma identity

Is it ever OK for doctors to lie to their patients?

Hepatitis C has a cure — but many Americans still lack access to it

Empower primary care with adequate payments and technology

State Dept. review finds Biden bears some blame for Afghanistan failures

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

explore

BIO to announce reorganization, senior leaders expected to depart

Why the advice to take all your antibiotics may be wrong

Hey, doctors: Don't be no

Lawmakers grill UnitedHealth CEO on Change cyberattack

The effects of a landmark ruling on DNA ownership are becoming clearer

How a small hospital in rural Puerto Rico survived Hurricane Maria

hotspot

entertainment

focus

leisure time